Date: Jan 04<sup>th</sup>, 2022

Your Name: Sebastian D Sahli

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Dr. Sahli has no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

\_X\_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04<sup>th</sup>, 2022

Your Name: Alexander Kaserer

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	Bayer AG (Switzerland)	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cuppert for attending	V None	
,	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Dr. Kaserer has received support from Bayer AG (Switzerland) for lecturing.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04<sup>th</sup>, 2022 Your Name: Julia Braun

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

**Single-center experience with 679 patients** 

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
3	in item #1 above).	V None	
5	Royalties or licenses	XNone	
4	Consulting fees	X None	

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6		XNone	
7	Company for attackling	V. Nene	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	X None	
,		XNONC	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	.1 Stock or stock options	XNone	
10			
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04th, 2022

Your Name:

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart

failure: Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this (e.g., if payments were made to you or to your relationship or indicate none (add rows as needed)

1 All support for the present X None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Time frame: past 36 months

M None

2 Grants or contracts from \_X\_None any entity (if not indicated in item #1 above).

3 Royalties or licenses

\_\_X\_None

4 Consulting fees

5 Payment or honoraria for lectures, presentations, speakers bureaus,		
manuscript writing or educational events		
6 Payment for expert testimony	_X_None	
7 Support for attending meetings and/or travel	_X_None	
8 Patents planned, issued pending	or _X_None	
9 Participation on a Data	X None	
Safety Monitoring Boar or Advisory Board		
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid o unpaid		
11 Stock or stock options	XNone	
12 Receipt of equipment, materials, drugs, med writing, gifts or other services	XNone	
13 Other financial or non financial interests	X_None	
	afficiat of interest in the following have	
summarize the above co	nflict of interest in the following box:	h-
	( John	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04th, 2022

Your Name: Yuliya Dahlem

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees		

meetings a  B Patents play pending  Participation Safety Mon Advisory B Leadership in other bo	anned, issued or	XNoneXNoneXNone		
8 Patents play pending 9 Participation Safety Mon Advisory B 10 Leadership in other both	and/or travel anned, issued or on on a Data			
Participation Safety Mon Advisory B Leadership in other bo	on on a Data	XNone		
Safety Mor Advisory B Leadership in other bo				
Leadership in other bo	nitoring Board or	XNone		
	or fiduciary role pard, society, or advocacy d or unpaid	XNone	•	
11 Stock or st	ock options	XNone		
	equipment, drugs, medical ts or other	XNone		
Other finar financial in	ncial or non- terests	XNone		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Zürich den 05.01.2022

Payment or honoraria for

X\_None

Dr. Yuliya Dahlem

Date: Jan 04<sup>th</sup>, 2022

Your Name: Muriel A Spahn

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees		

5	Payment or honoraria for	None
-	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	None
	financial interests	

None			

Please place an "X" next to the following statement to indicate your agreement:

\_X\_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04<sup>th</sup>, 2022 Your Name: Julian Rössler

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees		

5	Dayment or heneraria for	V None	
Э	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fo	llowing box:

Please place an "X" next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 06th, 2022

Your Name: BERNARD KRUGER

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	IN MAKEUPACHY BUT SAMAGEOUT TO HIS TOTAL TO THE ETHICAL THE CONTROL OF THE PROPERTY OF THE PRO

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
		V Name	
7	Support for attending meetings and/or travel	None	
	meemigs and/or travel		
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or	X None	
and a			
	Advisory Board	IN SEPTEMBER OF THE SECRETARY OF	· · · · · · · · · · · · · · · · · · ·
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

A ,		
Nohe		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04<sup>th</sup>, 2022

Your Name: Francesco Maisano, IRCCS Ospedale San Raffaele, Milano

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).		Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo
3	Royalties or licenses		Edwards Lifesciences, FM is Shareholder (including share options) of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech, Perifect
4	Consulting fees		Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Occlufit
5	Payment or honoraria for lectures, presentations,	XNone	

6	speakers bureaus, manuscript writing or educational events Payment for expert	X None	
ь	testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

Dr. Maisano reports: Grant and/or Research Institutional Support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo; Consulting fees, Honoraria personal and Institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Occlufit; Royalty Income/IP Rights Edwards Lifesciences, FM is Shareholder (including share options) of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech, Perifect.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 04<sup>th</sup>, 2022

Your Name: Donat R Spahn

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).		The Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland.
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for		Danube University of Krems, Austria, US Department of
	lectures, presentations,		Defense, Washington, USA, European Society of
	speakers bureaus,		Anesthesiology, Brussels, BE, Korean Society for Patient
	I		,
	manuscript writing or		Blood Management, Seoul, Korea, Korean Society of
	educational events		Anesthesiologists, Seoul, Korea, Network for the
			Advancement of Patient Blood Management,
			Haemostasis and Thrombosis, Paris, France, Alexion
			Pharmaceuticals Inc., Boston, MA, Baxalta Switzerland
			AG, Volketswil, Switzerland, Bayer AG, Zürich,
			Switzerland, B. Braun Melsungen AG, Melsungen,
			Germany, Boehringer Ingelheim GmbH, Basel,
			Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison
			Cedex, France and Baar, Switzerland, CSL Behring GmbH,
			Hattersheim am Main, Germany and Berne, Switzerland,
			Celgene International II Sàrl, Couvet, Switzerland, Daiichi
			Sankyo AG, Thalwil, Switzerland, Haemonetics,
			Braintree, MA, USA, Instrumentation Laboratory
			(Werfen), Bedford, MA, USA, LFB Biomédicaments,
			Courtaboeuf Cedex, France, Merck Sharp & Dohme,
			Kenilworth, New Jersey, USA, Novo Nordisk Health Care
			AG, Zurich, Switzerland, PAION Deutschland GmbH,
			Aachen, Germany, Pharmacosmos A/S, Holbaek,
			Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre
			Pharma, Alschwil, Switzerland, Portola Schweiz GmbH,
			Aarau, Switzerland, Roche Diagnostics International Ltd,
			Reinach, Switzerland, Sarstedt AG & Co., Sevelen,
			Switzerland and Nümbrecht, Germany, Shire Switzerland
			GmbH, Zug, Switzerland, Tem International GmbH,
			Munich, Germany, Vifor Pharma, Munich, Germany,
			Neuilly sur Seine, France and Villars-sur-Glâne,
			Switzerland, Vifor (International) AG, St. Gallen,
			Switzerland, Zuellig Pharma Holdings, Singapore,
			Singapore.
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel	V. Nana	
8	Patents planned, issued or	XNone	
9	pending  Participation on a Data	V None	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board		The ABC Trauma Faculty engagered by conservations
10	Leadership or fiduciary role		The ABC-Trauma Faculty, sponsored by unrestricted
	in other board, society,		educational grants from Novo Nordisk Health Care AG,
	committee or advocacy		Zurich, Switzerland, CSL Behring GmbH, Marburg,
	group, paid or unpaid		Germany, LFB Biomédicaments, Courtaboeuf Cedex,
			France and Octapharma AG, Lachen, Switzerland.
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	materials, arags, medical	l .	

	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Dr. Spahn's academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland. Dr. Spahn is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland. Dr. Spahn received honoraria / travel support for consulting or lecturing from: Danube University of Krems, Austria, US Department of Defense, Washington, USA, European Society of Anesthesiology, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Alexion Pharmaceuticals Inc., Boston, MA, Baxalta Switzerland AG, Volketswil, Switzerland, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Novo Nordisk Health Care AG, Zurich, Switzerland, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd, Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan 05<sup>th</sup>, 2022

Your Name: Markus J. Wilhelm

Manuscript Title: Predictors Associated with Mortality of Extracorporeal Life Support Therapy for acute heart failure:

Single-center experience with 679 patients

Manuscript number: JTD-21-1770-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None			
4	Consulting fees	None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	Yes	Berlin Heart, Berlin, Germany
	testimony		
7	Support for attending meetings and/or travel	Yes	Berlin Heart, Berlin, Germany
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Speaker's honoraria and travel expenses from Berlin Heart, Berlin, Germany			

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.